Compare, Analyse Biocon with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ACTAVIS (US) - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON    ACTAVIS
EQUITY SHARE DATA
    BIOCON
Mar-19
ACTAVIS
Dec-18
BIOCON /
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs70714,449-   
Low Rs5549,692-   
Sales per share (Unadj.) Rs91.93,544.2-  
Earnings per share (Unadj.) Rs16.7-1,141.6-  
Cash flow per share (Unadj.) Rs24.2373.5-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs101.614,618.3-  
Shares outstanding (eoy) m600.00332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.93.4 201.5%   
Avg P/E ratio x37.7-10.6 -356.9%  
P/CF ratio (eoy) x26.132.3 80.7%  
Price / Book Value ratio x6.20.8 751.4%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m378,3304,014,617 9.4%   
No. of employees `0006.116.9 36.3%   
Total wages/salary Rs m11,6530-   
Avg. sales/employee Rs Th8,994.369,752.4 12.9%   
Avg. wages/employee Rs Th1,900.70-   
Avg. net profit/employee Rs Th1,635.3-22,467.3 -7.3%   
INCOME DATA
Net Sales Rs m55,1441,178,815 4.7%  
Other income Rs m1,44422,543 6.4%   
Total revenues Rs m56,5881,201,358 4.7%   
Gross profit Rs m15,88330,891 51.4%  
Depreciation Rs m4,478503,918 0.9%   
Interest Rs m70968,024 1.0%   
Profit before tax Rs m12,140-518,508 -2.3%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0132,241 0.0%   
Tax Rs m2,123-6,571 -32.3%   
Profit after tax Rs m10,026-379,697 -2.6%  
Gross profit margin %28.82.6 1,099.1%  
Effective tax rate %17.51.3 1,379.9%   
Net profit margin %18.2-32.2 -56.4%  
BALANCE SHEET DATA
Current assets Rs m48,228483,488 10.0%   
Current liabilities Rs m30,376427,710 7.1%   
Net working cap to sales %32.44.7 684.2%  
Current ratio x1.61.1 140.5%  
Inventory Days Days6820 348.7%  
Debtors Days Days8666 128.9%  
Net fixed assets Rs m64,130133,435 48.1%   
Share capital Rs m3,0000-   
"Free" reserves Rs m57,9800-   
Net worth Rs m60,9804,862,062 1.3%   
Long term debt Rs m15,7661,712,108 0.9%   
Total assets Rs m121,9247,600,510 1.6%  
Interest coverage x18.1-6.6 -273.7%   
Debt to equity ratio x0.30.4 73.4%  
Sales to assets ratio x0.50.2 291.6%   
Return on assets %8.8-4.1 -214.7%  
Return on equity %16.4-7.8 -210.5%  
Return on capital %16.8-4.8 -346.1%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Net fx Rs m5,1070-   
CASH FLOW
From Operations Rs m11,546421,146 2.7%  
From Investments Rs m-7,138231,365 -3.1%  
From Financial Activity Rs m-2,417-722,813 0.3%  
Net Cashflow Rs m2,103-69,951 -3.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 74.67 Rs / USD

Compare BIOCON With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare BIOCON With: FDC  AUROBINDO PHARMA  WOCKHARDT  DIVIS LABORATORIES  J.B.CHEMICALS  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views On News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market (Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers (Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

India's Revival: A Once-in-a-generation Wealth Making Opportunity
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

BIOCON SHARE PRICE


Apr 9, 2021 (Close)

TRACK BIOCON

MORE ON BIOCON

BIOCON 8-QTR ANALYSIS

COMPARE BIOCON WITH

FEATURED VIDEOS

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

Kalyan Jewellers IPO: An Honest View

More Featured Videos

MARKET STATS